The Effect of Colistin Inhalation on Ventilator Associated Pneumonia
- Conditions
- Ventilator Associated Pneumonia
- Interventions
- Drug: Carbapenem + Aminoglycoside/ Quinolone
- Registration Number
- NCT03622450
- Lead Sponsor
- Nourhan Hassan Osama Thuraya Mohamed
- Brief Summary
The study has been conducted to measure the clinical outcome of early intervention with colistin inhalation in patients with ventilator associated pneumonia suspected to have multidrug resistant gram -ve bacteria
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Age 18 years
Patients presenting with signs of infection 48 hours of intubation
- Patients with documented bronchiectasis
Cystic fibrosis Known allergy to polymyxin. Patients presenting with chest infection or signs of infection before intubation.
Patients with creatinine clearance less than 30ml/min.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control arm Carbapenem + Aminoglycoside/ Quinolone Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function Medication arm Colistin Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
- Primary Outcome Measures
Name Time Method Assessment of Ventilatory status 7 to 10 days Pf ratio measurement
- Secondary Outcome Measures
Name Time Method Days of mechanical ventilation 35 Days Deescalation in the ventilation mode and trials until successful weaning.
Time till the occurence of sepsis 35 Days long standing ventilator associated pneumonia with failure of treatment can lead to sepsis
Mortality as an outcome of long stand untreatable ventilator associated pneumonia 35 days is the mortality due to sepsis of other causes
Length of stay in the icu 35 days How long will the patient stay in the ICU according to failure of weaning and progression of the disease.